Oramed Pharmaceuticals Inc.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Oramed Pharmaceuticals specializes in developing oral drug delivery systems for injectable therapies, focusing on diabetes treatment in Israel.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-23 17:53 |
Takeover Announcement Report
Option Agreement for the Repurchase of Warrants
|
English | 316.7 KB | |
| 2025-07-23 17:53 |
Regulatory News Service
Option Agreement for the Repurchase of Warrants
|
English | 36.4 KB | |
| 2025-07-18 14:52 |
Proxy Solicitation & Information Statements
Other Report or Announcement
|
English | 1.4 MB | |
| 2025-07-18 14:52 |
Regulatory News Service
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-07-18 14:51 |
Annual Report
Other Report or Announcement
|
English | 448.1 KB | |
| 2025-07-18 14:51 |
Regulatory News Service
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-07-18 14:50 |
Annual Report
Other Report or Announcement
|
English | 359.9 KB | |
| 2025-07-18 14:50 |
Regulatory News Service
Other Report or Announcement
|
English | 36.4 KB | |
| 2025-06-10 11:06 |
Directors' Dealings
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 574.4 KB | |
| 2025-06-10 11:06 |
Foreign Filer Report
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Reznick Yehuda
|
English | 36.2 KB | |
| 2025-05-22 08:30 |
Transaction in Own Shares
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 92.1 KB | |
| 2025-05-22 08:30 |
Transaction in Own Shares
Form 8-K-a one-year extension of the Company’s current stock buyback program
|
Hebrew (modern) | 36.4 KB | |
| 2025-05-16 13:29 |
Quarterly Report
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 1.1 MB | |
| 2025-05-16 13:29 |
Foreign Filer Report
Form 10-Q-For the quarterly period ended March 31, 2025
|
English | 36.3 KB | |
| 2025-04-29 11:13 |
Takeover Announcement Report
FORM 8-K-entered into purchase agreement of 14,110,121 of Alpha Tau’s ordinary …
|
English | 400.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |